Evidence map›Paper›PMID 31665421›Full record

ArticleNeuro-oncology2020

Lack of association between modifiable exposures and glioma risk: a Mendelian randomization analysis.

Charlie N Saunders, Alex J Cornish, Ben Kinnersley, Philip J Law, Elizabeth B Claus, Dora Il'yasova, Joellen Schildkraut, Jill S Barnholtz-Sloan, Sara H Olson, Jonine L Bernstein and 10 more

Open access · hybridAbstract read
In one paragraph

Article in Neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 4 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 13 institutions in 5 countries.

Charlie N SaundersDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Alex J CornishDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Ben KinnersleyDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Philip J LawDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Elizabeth B ClausSchool of Public Health, Yale University, New Haven, Connecticut, USA.
Dora Il'yasovaDepartment of Epidemiology and Biostatistics, School of Public Health, Georgia State University, Atlanta, Georgia, USA.
Joellen SchildkrautDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.
Jill S Barnholtz-SloanDepartment of Population and Quantitative Health Sciences and the Cleveland Center for Health Outcomes Research, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Sara H OlsonDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jonine L BernsteinDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Rose K LaiDepartments of Neurology and Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Stephen ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Preetha RajaramanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
Christoffer JohansenDanish Cancer Society Research Center, Survivorship, Danish Cancer Society, Copenhagen, Denmark.
Robert B JenkinsDepartment of Laboratory Medicine and Pathology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, Minnesota, USA.
Beatrice S MelinDepartment of Radiation Sciences, Umeå University, Umeå, Sweden.
Margaret R WrenschDepartment of Neurological Surgery, School of Medicine, University of California San Francisco (UCSF), San Francisco, California, USA.
Marc SansonSorbonne University, National Center for Scientific Research, National Institute of Health and Medical Research (INSERM), Brain and Spinal Cord Institute, Paris, France.
Melissa L BondySection of Epidemiology and Population Sciences, Department of Medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
Richard S HoulstonDivision of Molecular Pathology, The Institute of Cancer Research, London, UK.
Institute of Cancer Research · GBDuke University Hospital · USMemorial Sloan Kettering Cancer Center · USNational Cancer Institute · USBaylor College of Medicine · USCase Western Reserve University · USDanish Cancer Society · DKSorbonne Université · FRUmeå University · SEUniversity of California, San Francisco · USUniversity of Southern California · USWinnMed · USYale University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Immune epigenetic biomarkers of survival in glioma epidemiologyR01CA207360 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIENCKE, JOHN K. · 2017 to 2021
$3.8M
Cancer Research UK C1298/A8362NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA207360
6 · The paper itself

Abstract

backgroundThe etiological basis of glioma is poorly understood. We have used genetic markers in a Mendelian randomization (MR) framework to examine if lifestyle, cardiometabolic, and inflammatory factors influence the risk of glioma. This methodology reduces bias from confounding and is not affected by reverse causation.

methodsWe identified genetic instruments for 37 potentially modifiable risk factors and evaluated their association with glioma risk using data from a genome-wide association study of 12 488 glioma patients and 18 169 controls. We used the estimated odds ratio of glioma associated with each of the genetically defined traits to infer evidence for a causal relationship with the following exposures:Lifestyle and dietary factors-height, plasma insulin-like growth factor 1, blood carnitine, blood methionine, blood selenium, blood zinc, circulating adiponectin, circulating carotenoids, iron status, serum calcium, vitamins (A1, B12, B6, E, and 25-hydroxyvitamin D), fatty acid levels (monounsaturated, omega-3, and omega-6) and circulating fetuin-A;Cardiometabolic factors-birth weight, high density lipoprotein cholesterol, low density lipoprotein cholesterol, total cholesterol, total triglycerides, basal metabolic rate, body fat percentage, body mass index, fasting glucose, fasting proinsulin, glycated hemoglobin levels, diastolic and systolic blood pressure, waist circumference, waist-to-hip ratio; andInflammatory factors- C-reactive protein, plasma interleukin-6 receptor subunit alpha and serum immunoglobulin E.

resultsAfter correction for the testing of multiple potential risk factors and excluding associations driven by one single nucleotide polymorphism, no significant association with glioma risk was observed (ie, PCorrected > 0.05).

conclusionsThis study did not provide evidence supporting any of the 37 factors examined as having a significant influence on glioma risk.

Indexed as

Brain NeoplasmsGliomaDietHumansInflammationLife StyleMendelian Randomization AnalysisMetabolismRisk FactorscancergliomaMendelian randomizationrisk

Identifiers

PMID31665421
PMCPMC7442418
OpenAlexW2982709191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.